Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385811712> ?p ?o ?g. }
- W4385811712 endingPage "3580" @default.
- W4385811712 startingPage "3580" @default.
- W4385811712 abstract "(1) Background: Good adherence to a Phe-restricted diet supplemented with an adequate amount of a protein substitute (PS) is important for good clinical outcomes in PKU. Glycomacropeptide (cGMP)-PSs are innovative, palatable alternatives to amino acid-based PSs (AA-PS). This study aimed to evaluate a new cGMP-PS in liquid and powder formats in PKU. (2) Methods: Children and adults with PKU recruited from eight centres were prescribed at least one serving/day of cGMP-PS for 7-28 days. Adherence, acceptability, and gastrointestinal tolerance were recorded at baseline and the end of the intervention. The blood Phe levels reported as part of routine care during the intervention were recorded. (3) Results: In total, 23 patients (powder group, n = 13; liquid group, n = 10) completed the study. The majority assessed the products to be palatable (77% of powder group; 100% of liquid group) and well tolerated; the adherence to the product prescription was good. A total of 14 patients provided blood Phe results during the intervention, which were within the target therapeutic range for most patients (n = 11) at baseline and during the intervention. (4) Conclusions: These new cGMP-PSs were well accepted and tolerated, and their use did not adversely affect blood Phe control." @default.
- W4385811712 created "2023-08-15" @default.
- W4385811712 creator A5001044005 @default.
- W4385811712 creator A5012040853 @default.
- W4385811712 creator A5017337502 @default.
- W4385811712 creator A5030548436 @default.
- W4385811712 creator A5036628516 @default.
- W4385811712 creator A5039096060 @default.
- W4385811712 creator A5045482763 @default.
- W4385811712 creator A5048169226 @default.
- W4385811712 creator A5060516527 @default.
- W4385811712 creator A5061508281 @default.
- W4385811712 creator A5061678971 @default.
- W4385811712 creator A5065066710 @default.
- W4385811712 creator A5066369622 @default.
- W4385811712 creator A5067808638 @default.
- W4385811712 creator A5074499146 @default.
- W4385811712 creator A5079578509 @default.
- W4385811712 creator A5085840094 @default.
- W4385811712 creator A5092637197 @default.
- W4385811712 date "2023-08-14" @default.
- W4385811712 modified "2023-09-27" @default.
- W4385811712 title "Evaluation of a New Glycomacropeptide-Based Protein Substitute in Powdered and Liquid Format in Patients with PKU" @default.
- W4385811712 cites W1915707355 @default.
- W4385811712 cites W1964471120 @default.
- W4385811712 cites W1980692505 @default.
- W4385811712 cites W1990591430 @default.
- W4385811712 cites W2002775640 @default.
- W4385811712 cites W2005469307 @default.
- W4385811712 cites W2015131379 @default.
- W4385811712 cites W2019843119 @default.
- W4385811712 cites W2026158953 @default.
- W4385811712 cites W2028607122 @default.
- W4385811712 cites W2038837313 @default.
- W4385811712 cites W203943965 @default.
- W4385811712 cites W2072418931 @default.
- W4385811712 cites W2073907027 @default.
- W4385811712 cites W2077675998 @default.
- W4385811712 cites W2099620259 @default.
- W4385811712 cites W2107406829 @default.
- W4385811712 cites W2110283085 @default.
- W4385811712 cites W2110312890 @default.
- W4385811712 cites W2116539018 @default.
- W4385811712 cites W2122695607 @default.
- W4385811712 cites W2126537899 @default.
- W4385811712 cites W2136629989 @default.
- W4385811712 cites W2149285529 @default.
- W4385811712 cites W2151598366 @default.
- W4385811712 cites W2163408635 @default.
- W4385811712 cites W2336922729 @default.
- W4385811712 cites W2397617100 @default.
- W4385811712 cites W2460747436 @default.
- W4385811712 cites W2512099571 @default.
- W4385811712 cites W2551891474 @default.
- W4385811712 cites W2571262027 @default.
- W4385811712 cites W2581702837 @default.
- W4385811712 cites W2587254500 @default.
- W4385811712 cites W2601583588 @default.
- W4385811712 cites W2605597690 @default.
- W4385811712 cites W2761810763 @default.
- W4385811712 cites W2783823678 @default.
- W4385811712 cites W2810159771 @default.
- W4385811712 cites W2884421470 @default.
- W4385811712 cites W2897437166 @default.
- W4385811712 cites W2897441431 @default.
- W4385811712 cites W2918080506 @default.
- W4385811712 cites W2921713659 @default.
- W4385811712 cites W3007014463 @default.
- W4385811712 cites W3015478667 @default.
- W4385811712 cites W3108777433 @default.
- W4385811712 cites W3140815554 @default.
- W4385811712 cites W3172822970 @default.
- W4385811712 cites W3209369260 @default.
- W4385811712 cites W4200007750 @default.
- W4385811712 cites W4211112701 @default.
- W4385811712 cites W4212921553 @default.
- W4385811712 cites W4249791806 @default.
- W4385811712 cites W4309721951 @default.
- W4385811712 doi "https://doi.org/10.3390/nu15163580" @default.
- W4385811712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37630769" @default.
- W4385811712 hasPublicationYear "2023" @default.
- W4385811712 type Work @default.
- W4385811712 citedByCount "0" @default.
- W4385811712 crossrefType "journal-article" @default.
- W4385811712 hasAuthorship W4385811712A5001044005 @default.
- W4385811712 hasAuthorship W4385811712A5012040853 @default.
- W4385811712 hasAuthorship W4385811712A5017337502 @default.
- W4385811712 hasAuthorship W4385811712A5030548436 @default.
- W4385811712 hasAuthorship W4385811712A5036628516 @default.
- W4385811712 hasAuthorship W4385811712A5039096060 @default.
- W4385811712 hasAuthorship W4385811712A5045482763 @default.
- W4385811712 hasAuthorship W4385811712A5048169226 @default.
- W4385811712 hasAuthorship W4385811712A5060516527 @default.
- W4385811712 hasAuthorship W4385811712A5061508281 @default.
- W4385811712 hasAuthorship W4385811712A5061678971 @default.
- W4385811712 hasAuthorship W4385811712A5065066710 @default.
- W4385811712 hasAuthorship W4385811712A5066369622 @default.
- W4385811712 hasAuthorship W4385811712A5067808638 @default.